Form 8-K PALVELLA THERAPEUTICS, For: Sep 24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls 1% as traders digest escalation in US-Iran strikes
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Palvella Therapeutics (PVLA) PT Raised to $90 at Oppenheimer
September 24, 2025 1:17 PM EDTOppenheimer analyst Trevor Allred raised the price target on Palvella Therapeutics (NASDAQ: PVLA) to $90.00 (from $85.00) while maintaining a Outperform rating.
The analyst comments "Palvella hosted a webcast this morning demonstrating the unmet need and high market potential for Qtorin rapamycin in clinically significant angiokeratomas.... More
